INTRASENSE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.325 EUR | +1.56% |
|
+3.50% | -9.72% |
| Apr. 17 | Intrasense: an innovative solution for cancer monitoring | CF |
| Apr. 09 | Guerbet: CE certificate for a platform | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1,000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system.
Calendar
2024-07-10
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.72% | 17.81M | |
| +2.64% | 207B | |
| +1.80% | 175B | |
| +8.59% | 132B | |
| +16.47% | 99.1B | |
| -3.42% | 60.89B | |
| +12.71% | 52.04B | |
| -6.61% | 45.48B | |
| -4.53% | 38.81B | |
| +9.27% | 38.77B |
- Stock Market
- Equities
- ALINS Stock
- News Intrasense
- Intrasense : Targets $6 Million in Rights Offering
